MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2026.1862815

Медицинская библиотека · Frontiers in immunology · 2026

Neoadjuvant chemoradiotherapy versus immunochemotherapy in esophageal squamous cell carcinoma: a propensity-matched analysis of response, survival, lymph node pattern, and immune microenvironment.

Yehan Zhou, Zhou Xiaoqing, Hu Shangzhi, Yang Qiao, Leng Xuefeng, He Wenwu, Wang Qifeng, Lyu Jiahua, Qing Haomiao, Liu Yang, Yang Hong

СтатьяСравнительное исследованиеПеревод в очереди

Аннотация

OBJECTIVE

To compare efficacy, survival and tumor immune microenvironment between neoadjuvant chemoradiotherapy (NCRT) and neoadjuvant immunochemotherapy (NICT) in patients with esophageal squamous cell carcinoma (ESCC) to guide individualized treatment.

METHODS

A total of 346 locally advanced ESCC patients after 1:1 propensity score matching were retrospectively analyzed. Pathological, radiological and multiplex immunofluorescence assessments were performed, and survival outcomes were evaluated.

RESULTS

NCRT resulted in significantly greater tumor volume reduction (22.09 vs. 15.37 mm³), lower residual primary tumor ratio (14.10% vs. 32.23%), higher tumor downstaging and pathological complete response (pCR) rates (all p < 0.05). NCRT showed more prominent lymph node regression adjacent to the primary tumor than in peripheral nodes. Overall survival (OS) and recurrence-free survival (RFS) were comparable between groups. Among pCR patients, NICT achieved significantly better OS (p = 0.0051) and RFS (p = 0.018), while NCRT was associated with superior RFS in non-pCR patients (p = 0.0099). In the NICT group, high PD-L1 expression and low tumor burden tended to correlate with pCR. Immune microenvironment analysis revealed fewer immunosuppressive T cells and immune-evasive tumor cells in the NICT group.

CONCLUSION

NCRT presents superior local tumor regression, while NICT benefits pCR patients by optimizing the immune microenvironment. High PD-L1 expression and low tumor burden favor NICT. These findings support individualized neoadjuvant strategy selection for ESCC.

Для цитирования: Yehan Zhou, Zhou Xiaoqing, Hu Shangzhi, Yang Qiao, Leng Xuefeng, He Wenwu, Wang Qifeng, Lyu Jiahua, Qing Haomiao, Liu Yang, Yang Hong. Neoadjuvant chemoradiotherapy versus immunochemotherapy in esophageal squamous cell carcinoma: a propensity-matched analysis of response, survival, lymph node pattern, and immune microenvironment.. Frontiers in immunology. 2026. DOI: 10.3389/fimmu.2026.1862815.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.